MedTrace Logo

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT02439125 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-04-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of eltoprazine to treat levodopa-induced dyskinesia in patients with Parkinson's disease

Conditions

Interventions

DRUG

Eltoprazine HCl

2.5 mg b.i.d. orally for 3 weeks

DRUG

Eltoprazine HCl

5.0 mg b.i.d. orally for 3 weeks

DRUG

Eltoprazine HCl

7.5 mg b.i.d. orally for 3 weeks

DRUG

Placebo

b.i.d. orally for 3 weeks

Sponsors & Collaborators

  • Amarantus BioScience Holdings, Inc.

    lead INDUSTRY

Principal Investigators

  • Charlotte Keywood, MBBS,MRCP, · Amarantus BioScience Holdings, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02439125 on ClinicalTrials.gov